(NASDAQ:NVDA) Shares Sold by Engrave Wealth Partners LLC South Shore Capital Advisors Takes Position in Verizon Communications Inc.Graypoint LLC Sells 291 Shares of Micron Technology, Inc.Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with 's FREE daily email newsletter. Allstate: A Safe Stock During Volatile Times, Which Will Benefit From Rising Rates.A10 Networks: Key 5G Infrastructure Stock that’s Beating the Market.Commercial Metals Company Is Ready To Rebound.The Institutions Turn The Tide For Jabil.Get a free copy of the research report on Tyme Technologies (TYME).Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. Tyme Technologies, Inc, a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Institutional investors and hedge funds own 21.00% of the company’s stock. now owns 2,084,696 shares of the company’s stock valued at $2,147,000 after buying an additional 166,889 shares in the last quarter. lifted its position in shares of Tyme Technologies by 8.7% during the 3rd quarter. Renaissance Technologies LLC purchased a new position in shares of Tyme Technologies during the 3rd quarter valued at approximately $571,000. Morgan Stanley now owns 276,924 shares of the company’s stock valued at $493,000 after buying an additional 219,507 shares in the last quarter. Morgan Stanley lifted its position in shares of Tyme Technologies by 382.3% during the 1st quarter. GSA Capital Partners LLP purchased a new position in shares of Tyme Technologies during the 4th quarter valued at approximately $109,000. Institutional investors have recently added to or reduced their stakes in the business. The firm has a market cap of $43.71 million, a P/E ratio of -1.95 and a beta of 1.10. The firm’s 50 day moving average is $0.29 and its 200-day moving average is $0.41. has a fifty-two week low of $0.22 and a fifty-two week high of $2.02. The company’s stock had a trading volume of 407,648 shares, compared to its average volume of 810,586. NASDAQ:TYME traded down $0.01 during midday trading on Thursday, hitting $0.25. The stock was sold at an average price of $0.33, for a total transaction of $6,600.00. On Monday, March 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock.The stock was sold at an average price of $0.34, for a total transaction of $6,800.00. On Monday, March 28th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock.The stock was sold at an average price of $0.35, for a total transaction of $7,000.00. On Monday, April 4th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. ![]() The shares were sold at an average price of $0.34, for a total transaction of $6,800.00.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |